Citation: | LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui. Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 180-186. DOI: 10.12290/xhyxzz.2021-0764 |
[1] |
Sand KM, Bern M, Nilsen J, et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics[J]. Front Immunol, 2014, 5: 682.
|
[2] |
Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy[J]. Chem Soc Rev, 2016, 45: 1432-1456. DOI: 10.1039/C5CS00158G
|
[3] |
Evans HM, Schulemann W. The Action of Vital Stains Belonging to the Benzidine Group[J]. Science, 1914, 39: 443-454. DOI: 10.1126/science.39.1004.443
|
[4] |
Freedman FB, Johnson JA. Equilibrium and kinetic properties of the Evans blue-albumin system[J]. Am J Physiol, 1969, 216: 675-681. DOI: 10.1152/ajplegacy.1969.216.3.675
|
[5] |
Niu G, Lang L, Kiesewetter DO, et al. In Vivo Labeling of Serum Albumin for PET[J]. J Nucl Med, 2014, 55: 1150-1156. DOI: 10.2967/jnumed.114.139642
|
[6] |
Wang Y, Lang L, Huang P, et al. In vivo albumin labeling and lymphatic imaging[J]. Proc Natl Acad Sci U S A, 2015, 112: 208-213. DOI: 10.1073/pnas.1414821112
|
[7] |
Zhang J, Lang L, Zhu Z, et al. Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB[J]. J Nucl Med, 2015, 56: 1609-1614. DOI: 10.2967/jnumed.115.159640
|
[8] |
Zang J, Liu Q, Sui H, et al. Combined (68)Ga-NOTA-Evans Blue Lymphoscintigraphy and (68)Ga-NOTA-RM26 PET/CT Evaluation of Sentinel Lymph Node Metastasis in Breast Cancer Patients[J]. Bioconjug Chem, 2020, 31: 396-403. DOI: 10.1021/acs.bioconjchem.9b00789
|
[9] |
Long X, Zhang J, Zhang D, et al. Microsurgery guided by sequential preoperative lymphography using (68)Ga-NEB PET and MRI in patients with lower-limb lymphedema[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1501-1510. DOI: 10.1007/s00259-017-3676-6
|
[10] |
Zhang W, Wu P, Li F, et al. Potential Applications of Using 68Ga-Evans Blue PET/CT in the Evaluation of Lymphatic Disorder: Preliminary Observations[J]. Clin Nucl Med, 2016, 41: 302-308. DOI: 10.1097/RLU.0000000000001171
|
[11] |
Hou G, Jiang Y, Xu W, et al. (68)Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with (99m)TC-ASC lymphoscintigraphy: a prospective study[J]. Orphanet J Rare Dis, 2021, 16: 279. DOI: 10.1186/s13023-021-01895-1
|
[12] |
Hou G, Hou B, Jiang Y, et al. 68Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema[J]. Clin Nucl Med, 2019, 44: 439-445. DOI: 10.1097/RLU.0000000000002584
|
[13] |
Chen H, Tong X, Lang L, et al. Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography[J]. Theranostics, 2017, 7: 2363-2376. DOI: 10.7150/thno.19898
|
[14] |
Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2: S51-S61.
|
[15] |
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 66-74. DOI: 10.2967/jnumed.117.202275
|
[16] |
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. DOI: 10.1056/NEJMoa1607427
|
[17] |
Tian R, Jacobson O, Niu G, et al. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy[J]. Theranostics, 2018, 8: 735-745. DOI: 10.7150/thno.23491
|
[18] |
Bandara N, Jacobson O, Mpoy C, et al. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent[J]. Bioconjug Chem, 2018, 29: 2448-2454. DOI: 10.1021/acs.bioconjchem.8b00341
|
[19] |
Zhang J, Wang H, Jacobson O, et al. Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 1699-1705. DOI: 10.2967/jnumed.118.209841
|
[20] |
Wang H, Cheng Y, Zhang J, et al. Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study[J]. Theranostics, 2018, 8: 3308-3316. DOI: 10.7150/thno.25919
|
[21] |
Liu Q, Cheng Y, Zang J, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 947-957. DOI: 10.1007/s00259-019-04530-1
|
[22] |
Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE[J]. J Nucl Med, 2021, 62: 386-392. DOI: 10.2967/jnumed.120.248658
|
[23] |
Bergsma H, Konijnenberg MW, Kam BL, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 453-463. DOI: 10.1007/s00259-015-3193-4
|
[24] |
Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 1238-1246. DOI: 10.1007/s00259-015-3041-6
|
[25] |
Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 205-210. DOI: 10.1007/s00259-013-2547-z
|
[26] |
Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience[J]. Pancreas, 2014, 43: 518-525. DOI: 10.1097/MPA.0000000000000113
|
[27] |
Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 5-19. DOI: 10.1007/s00259-014-2893-5
|
[28] |
Paganelli G, Sansovini M, Ambrosetti A, et al. 177Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase Ⅱ study[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 1845-1851. DOI: 10.1007/s00259-014-2735-5
|
[29] |
Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2013, 54: 1857-1861. DOI: 10.2967/jnumed.112.119347
|
[30] |
Jonathan S, Edward W, Beth C, et al. NETTER-1 Phase Ⅲ in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results[J]. J Nucl Med, 2016, 57: 629.
|
[31] |
Brieau B, Hentic O, Lebtahi R, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy[J]. Endocr Relat Cancer, 2016, 23: L17-L23. DOI: 10.1530/ERC-15-0543
|
[32] |
Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85.
|
[33] |
Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J]. Hum Pathol, 2007, 38: 696-701. DOI: 10.1016/j.humpath.2006.11.012
|
[34] |
Wang W, Tavora F, Sharma R, et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma[J]. Urol Oncol, 2009, 27: 525-528. DOI: 10.1016/j.urolonc.2008.04.007
|
[35] |
Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol Histopathol, 2004, 19: 715-718.
|
[36] |
Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies[J]. J Nucl Med, 2015, 56: 1169-1176. DOI: 10.2967/jnumed.115.158550
|
[37] |
Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer[J]. J Nucl Med, 2015, 56: 914-920. DOI: 10.2967/jnumed.114.147413
|
[38] |
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. DOI: 10.1056/NEJMoa2107322
|
[39] |
Wang Z, Jacobson O, Tian R, et al. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent (90)Y-DOTA-EB-MCG[J]. Bioconjug Chem, 2018, 29: 2309-2315. DOI: 10.1021/acs.bioconjchem.8b00292
|
[40] |
Wang Z, Tian R, Niu G, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors[J]. Bioconjug Chem, 2018, 29: 3213-3221. DOI: 10.1021/acs.bioconjchem.8b00556
|
[41] |
Zang J, Fan X, Wang H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 148-158. DOI: 10.1007/s00259-018-4096-y
|
[42] |
Zang J, Liu Q, Sui H, et al. (177)Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer[J]. J Nucl Med, 2020, 61: 1772-1778. DOI: 10.2967/jnumed.120.242263
|
[43] |
Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19: 825-833. DOI: 10.1016/S1470-2045(18)30198-0
|
[1] | XU Kexin, LI Guozhuang, WU Zhihong, ZHANG Jianguo, DISCO(Deciphering Disorders Involving Scoliosis & Comorbidities) Study Group, WU Nan. Progress in Clinical Diagnosis and Management of Short Stature in Ehlers-Danlos Syndromes[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 163-170. DOI: 10.12290/xhyxzz.2024-0173 |
[2] | ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605 |
[3] | LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. DOI: 10.12290/xhyxzz.2023-0236 |
[4] | QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023 |
[5] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
[6] | ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180 |
[7] | CHEN Yue. Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 187-191. DOI: 10.12290/xhyxzz.2021-0557 |
[8] | WANG Guochang, ZHU Zhaohui. Molecular Imaging-guided Precise Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 165-168. DOI: 10.12290/xhyxzz.2021-0773 |
[9] | Noyes' Knee Disorders: Surgery, Rehabilitation, Clinical Outcomes(2nd ed.)(2016)[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(1): 18-18. |
[10] | MAIMAITI Nu-rong-gu-li, Hua-bing ZHANG, Xiao-ping XING. Clinical and Genetic Analysis of a Uyghur Patient with Gitelman's Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 427-431. DOI: 10.3969/j.issn.1674-9081.2015.06.006 |